Crossover randomized multicentre clinical trial comparing the efficacy and tolerability of fixed-combinations of 0.1% brimonidine/0.5% timolol versus 1% dorzolamide/0.5% timolol as adjunctive therapies to prostaglandin analogues: Aibeta Crossover Study
Abstract:This multicentre, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed-combinations 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues. A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for eight weeks. These… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.